Gastrointestinal Cancer

News alerts, weekly reports and conference planners

HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5d	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5d	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) trastuzumab + tucatinib Sensitive : A2 NCCN - 1wk	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week trastuzumab + tucatinib Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week (New B) pembrolizumab Sensitive : B Merck (MSD) Press Release - 1wk	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week pembrolizumab Sensitive : B Merck (MSD) Press Release - 1 week - (New B)
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria Nat Med - 1 week (New C3) trametinib + dabrafenib + PDR001 Sensitive : C2 Nat Med - 1wk	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria Nat Med - 1 week trametinib + dabrafenib + PDR001 Sensitive : C2 Nat Med - 1 week - (New C3)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 2 weeks (New B) bevacizumab + atezolizumab Sensitive : A1 Businesswire - 2wk	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 2 weeks bevacizumab + atezolizumab Sensitive : A1 Businesswire - 2 weeks - (New B)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) sorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks sorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	fruquintinib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) fruquintinib Sensitive : A1 ASCO-GI 2023 - 2wk	fruquintinib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks fruquintinib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks (New C3) cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2wk	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) IMAB362 Sensitive : B ASCO-GI 2023 - 2wk	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks IMAB362 Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative	Gastric Cancer	CLDN18.2 positive + HER-2 negative	Gastric Cancer	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) IMAB362 Sensitive : B ASCO-GI 2023 - 2wk	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks IMAB362 Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : A1 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks (New C3) futibatinib Sensitive : A1 N Engl J Med - 2wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks futibatinib Sensitive : A1 N Engl J Med - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks (New C3) futibatinib Sensitive : A1 N Engl J Med - 2wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks futibatinib Sensitive : A1 N Engl J Med - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) nivolumab + ipilimumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab + ipilimumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks (New A1) trastuzumab + tucatinib Sensitive : A1 FDA - 2wk	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks trastuzumab + tucatinib Sensitive : A1 FDA - 2 weeks - (New A1)
PD-L1 expression	Biliary Tract Cancer	PD-L1 expression	Biliary Tract Cancer	nivolumab Sensitive: C1 - Off-label ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C1 - Off-label ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C1 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 2wk	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	regorafenib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) regorafenib Sensitive : C2 ASCO-GI 2023 - 2wk	regorafenib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks regorafenib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2wk	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C2 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C2 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) bevacizumab Sensitive : C2 ASCO-GI 2023 - 2wk	bevacizumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks bevacizumab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	anlotinib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) anlotinib Sensitive : C2 ASCO-GI 2023 - 2wk	anlotinib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks anlotinib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2wk	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AB011 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) AB011 Sensitive : C2 ASCO-GI 2023 - 2wk	AB011 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks AB011 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) CMG901 Sensitive : C2 ASCO-GI 2023 - 2wk	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks CMG901 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) CMG901 Sensitive : C2 ASCO-GI 2023 - 2wk	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks CMG901 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Cholangiocarcinoma	MDM2 amplification	Cholangiocarcinoma	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C2 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Biliary Tract Cancer	MDM2 amplification	Biliary Tract Cancer	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C2 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ZW25 Sensitive : C3 ASCO-GI 2023 - 2wk	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ZW25 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) panitumumab Sensitive : C3 ASCO-GI 2023 - 2wk	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks panitumumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks (New C3) erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 2wk	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive	Colorectal Cancer	BRAF wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AB011 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AB011 Sensitive : C3 ASCO-GI 2023 - 2wk	AB011 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AB011 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion	Cholangiocarcinoma	FGFR fusion	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	regorafenib Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) regorafenib Resistant : C3 ASCO-GI 2023 - 2wk	regorafenib Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks regorafenib Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	trifluridine/tipiracil Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trifluridine / tipiracil Resistant : C3 ASCO-GI 2023 - 2wk	trifluridine/tipiracil Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks trifluridine / tipiracil Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 2wk	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression	Gastroesophageal Junction Adenocarcinoma	CAPRIN-1 expression	Gastroesophageal Junction Adenocarcinoma	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2wk	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression	Gastric Cancer	CAPRIN-1 expression	Gastric Cancer	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2wk	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
THBS2-L	Colorectal Cancer	THBS2-L	Colorectal Cancer	ramucirumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ramucirumab Sensitive : C3 ASCO-GI 2023 - 2wk	ramucirumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ramucirumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C3 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Ampulla of Vater Carcinoma	MDM2 amplification	Ampulla of Vater Carcinoma	BI 907828 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C3 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Biliary Tract Cancer	KRAS mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification	Biliary Tract Cancer	HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R	Pancreatic Ductal Adenocarcinoma	KRAS G12R	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) FOLFIRINOX Sensitive : C3 ASCO-GI 2023 - 2wk	FOLFIRINOX Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks FOLFIRINOX Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R	Pancreatic Ductal Adenocarcinoma	KRAS G12R	Pancreatic Ductal Adenocarcinoma	paclitaxel + gemcitabine Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + gemcitabine Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + gemcitabine Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + gemcitabine Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) irinotecan Sensitive : C3 ASCO-GI 2023 - 2wk	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks irinotecan Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) irinotecan Sensitive : C3 ASCO-GI 2023 - 2wk	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks irinotecan Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C3 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + RAS mutation	Colorectal Cancer	MSI-H/dMMR + RAS mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks (New C4) palbociclib Sensitive : C4 Onco Targets Ther - 2wk	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks palbociclib Sensitive : C4 Onco Targets Ther - 2 weeks - (New C4)
CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	capmatinib Sensitive: C4 – Case Studies The Oncologist - 2 weeks (New C4) capmatinib Sensitive : C4 The Oncologist - 2wk	capmatinib Sensitive: C4 – Case Studies The Oncologist - 2 weeks capmatinib Sensitive : C4 The Oncologist - 2 weeks - (New C4)
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) nivolumab Sensitive : D ASCO-GI 2023 - 2wk	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks nivolumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) pembrolizumab Sensitive : D ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation	Colorectal Cancer	PIK3CA mutation + KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1

Gastrointestinal Cancer

Associations(3077)

Associations
(3077)